LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

Inicio・Lista de Acciones・Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Cerrado

Sector Salud

470.69 -1.11

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

469.71

Máximo

471.55

Métricas clave
By Trading Economics
Ingresos	-4.7B -3.6B
Ventas	-40M 2.7B
P/B Media del Sector	30.09 104.138
BPA	-12.83
Margen de beneficio	-135.608
Empleados	5,400
EBITDA	1.3B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+9.34 upside

Dividendos
By Dow Jones
Próximas Ganancias	4 nov 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-41M 122B
Apertura anterior	471.8
Cierre anterior	470.69

Noticias sobre sentimiento de mercado

By Acuity

95%

4 / 389 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

474.91 / 477.66 Soporte y Resistencia

Vertex Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 ago 2024, 20:45 UTC

Ganancias

Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

6 may 2024, 20:37 UTC

Ganancias

Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug

10 abr 2024, 22:48 UTC

Principales Movimientos del Mercado

Adquisiciones, fusiones, absorciones

Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition

10 abr 2024, 21:40 UTC

Principales Movimientos del Mercado

Adquisiciones, fusiones, absorciones

Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.

10 abr 2024, 21:24 UTC

Adquisiciones, fusiones, absorciones

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update

10 abr 2024, 20:30 UTC

Principales Noticias

Adquisiciones, fusiones, absorciones

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion

26 sept 2024, 14:20 UTC

Adquisiciones, fusiones, absorciones

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

1 ago 2024, 20:30 UTC

Ganancias

Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

1 ago 2024, 20:03 UTC

Ganancias

Vertex Pharmaceuticals: Raised Full Yr Pdt Rev Guidanceto $10.65B - $10.85 B >VRTX

1 ago 2024, 20:02 UTC

Ganancias

Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance >VRTX

1 ago 2024, 20:02 UTC

Ganancias

Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX

27 jun 2024, 20:15 UTC

Adquisiciones, fusiones, absorciones

Vertex Also Sees About $200M of Transaction-Related Compensation Expense Associated With Acceleration of Unvested Awards Pursuant to Alpine Equity Incentive Plans

27 jun 2024, 20:14 UTC

Adquisiciones, fusiones, absorciones

Vertex Pharmaceuticals Expects to Record About $4.4B One-Time Acquired In-Process R&D Expense Related to May Purchase of Alpine Immune Sciences

6 may 2024, 21:00 UTC

Ganancias

Vertex Beats Quarterly Forecasts, But Its Pipeline Remains Key -- IBD

6 may 2024, 20:15 UTC

Ganancias

Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook -- IBD

6 may 2024, 20:03 UTC

Ganancias

Vertex Pharmaceuticals: Reiterated Full Yr 2024 Fincl Guidance, Including Pdt Rev Guidance of $10.55B to $10.75 B >VRTX

6 may 2024, 20:03 UTC

Ganancias

Vertex Pharmaceuticals 1Q Rev $2.69B >VRTX

6 may 2024, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 1Q Net $1.1B >VRTX

6 may 2024, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 1Q Adj EPS $4.76 >VRTX

6 may 2024, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 1Q EPS $4.21 >VRTX

23 abr 2024, 18:54 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Vertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk

11 abr 2024, 20:18 UTC

Adquisiciones, fusiones, absorciones

Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It -- IBD

11 abr 2024, 16:54 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Alpine Deal Seen Giving Vertex New Expertise -- Market Talk

11 abr 2024, 14:46 UTC

Adquisiciones, fusiones, absorciones

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com

11 abr 2024, 13:47 UTC

Acciones populares

Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands -- WSJ

10 abr 2024, 21:47 UTC

Adquisiciones, fusiones, absorciones

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update

10 abr 2024, 21:09 UTC

Adquisiciones, fusiones, absorciones

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B -- Update

10 abr 2024, 20:46 UTC

Adquisiciones, fusiones, absorciones

Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal -- IBD

10 abr 2024, 20:15 UTC

Adquisiciones, fusiones, absorciones

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B

10 abr 2024, 20:04 UTC

Adquisiciones, fusiones, absorciones

Alpine Immune Sciences: Vertex Will Acquire Alpine for $65 Per Shr or Approximately $4.9B in Cash, Transaction Approved by Both Boards of Directors, Anticipated to Close in 2Q >ALPN

Comparación entre iguales

Cambio de precio

Vertex Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

9.34% repunte

Estimación a 12 meses

Media 515.11 USD 9.34%

Máximo 600 USD

Mínimo 361 USD

De acuerdo con 26 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Vertex Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

26 ratings

Comprar

Mantener

Vender

De acuerdo con 26 analistas que ofrecen calificaciones bursátiles a para Vertex Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

474.91 / 477.66Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimiento

By Acuity

4 / 389 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.